EUVIMEDEUVIMED entdecken
Open Access

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors

Jingping Yang, Isaiah Deresa, Wei-Hsien Ho, Hua Long, Daniel Maslyar iD, Arnon Rosenthal, Spencer C Liang, Andrew Pincetic iD

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2200157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Jingping Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Alector, Inc., South San Francisco, CA. Hauptthemen laut MEDLINE: Receptors, Fc, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Alector, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antagonizing the CD47–signal regulatory protein (SIRP)α pathway, a critical myeloid checkpoint, promotes antitumor immunity. In this study, we describe the development of AL008, a pan-allelic, SIRPα-specific Ab that triggers the degradation of SIRPα and, concurrently, stimulates FcγR activation of myeloid cells through an engineered Fc domain. AL008 showed superior enhancement of phagocytosis of tumor cells opsonized with antitumor Ag Abs compared with another SIRPα Ab tested. Unlike ligand-blocking SIRPα Abs, AL008 demonstrated single-agent activity by increasing tumor cell engulfment by human monocyte-derived macrophages even in the absence of opsonizing agents. This effect was due to enhanced Fc function, as blocking FcγR2A abrogated AL008-mediated phagocytic activity. AL008 also promoted human monocyte-derived dendritic cell–mediated T cell proliferation. In humanized mouse models, AL008 induced internalization of SIRPα and increased expression of CD86 and HLA-DR on human tumor-associated macrophages, confirming that the mechanism of action is retained in vivo. Monotherapy treatment with AL008 significantly reduced tumor growth in humanized mice implanted with human MDA-MB-231 tumor cells. AL008 also significantly potentiated the effects of T cell checkpoint blockade with anti–programmed death ligand-1 in syngeneic tumor models. This dual and specific mechanism of AL008, to our knowledge, provides a novel therapeutic strategy for targeting myeloid cells for immune activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, FcNeoplasmsHumansMiceAnimalsImmunotherapyPhagocytosisMacrophagesAntigens, DifferentiationCD47 Antigen

Substanzen

Receptors, FcAntigens, DifferentiationCD47 Antigen

Autor:innen und Institutionen

  • Alector, Inc., South San Francisco, CA.

ORCID-Profile: Daniel Maslyar, Andrew Pincetic

Förderung

  • Alector, Inc

Zitieren

APA

Yang, J., Deresa, I., Ho, W. H., Long, H., Maslyar, D., Rosenthal, A., Liang, S. C., & Pincetic, A. (2023). AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200157

Vancouver

Yang J, Deresa I, Ho WH, Long H, Maslyar D, Rosenthal A, et al. AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200157

BibTeX
@article{Yang2023,
  author = {Yang, Jingping and Deresa, Isaiah and Ho, Wei-Hsien and Long, Hua and Maslyar, Daniel and Rosenthal, Arnon and Liang, Spencer C and Pincetic, Andrew},
  title = {AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2200157}
}
Kostenlos starten →